SOHO 2020 | Impact of COVID-19 on CAR T-cell therapies
David L. Porter
David L. Porter, MD, University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, explores the impact of the COVID-19 pandemic on the treatment and management of patients with hematological malignancies currently recieving CAR T-cell therapies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
Related videos
1:53 European regulation and access to advanced therapies
Aurélie Mahalatchimy
5:40 Gene editing: legal and ethical considerations
Aurélie Mahalatchimy
3:02 NK-CAR immunotherapy development over the past 12 months
Evelyn Ullrich
1:17 NK-CAR immunotherapy: the next steps
Evelyn Ullrich
3:06 Safety and outcome of prophylactic high-dose donor CD45RO+ memory T-cells after allo-HSCT
Mercedes Gasior Kabat
